November 14, 2013
Former SAC Capital Advisors LP manager Mathew Martoma said in New York federal court Wednesday that prosecutors are trying to gain a "tactical advantage" in his criminal trial over alleged insider trading related to an Alzheimer's drug, by seeking to bar him from obtaining key documents in his civil case.
July 31, 2013
The government's insider trading indictment of SAC Capital Advisors LP warrants immediate approval of the hedge fund's long-delayed $600 million civil settlement with U.S. regulators, a class of pharmaceutical company investors suing the firm told a New York federal judge Tuesday.
April 16, 2013
A New York federal judge on Tuesday approved the U.S. Securities and Exchange Commission's $600 million insider trading settlement with SAC Capital Advisors LLC — but conditioned the deal on the outcome of a Second Circuit case over the agency's policy of allowing defendants to neither admit nor deny wrongdoing.
April 04, 2013
The U.S. Securities and Exchange Commission on Wednesday again urged a New York federal judge to approve its $600 million insider trading settlement with SAC Capital Advisors LP affiliate CR Intrinsic Investors LLC, defending its use of its controversial no-admit, no-deny policy.
March 28, 2013
Approval of a landmark $600 million settlement to end the U.S. Securities and Exchange Commission's insider trading suit against SAC Capital Advisors LP could be hindered by the hedge fund's unwillingness to admit wrongdoing, a New York federal judge indicated Thursday.
March 15, 2013
The U.S. Securities and Exchange Commission's record-breaking $600 million insider trading settlement with a unit of hedge fund SAC Capital Advisors LP sends a strong message to hedge funds that the SEC is getting more aggressive and isn't afraid to take on the big fish, experts say.
March 15, 2013
A unit of hedge fund SAC Capital Advisors LP has agreed to pay more than $600 million to resolve allegations that it traded on inside information about an experimental Alzheimer's drug, the largest ever settlement in an insider trading suit, the U.S. Securities and Exchange Commission said Friday.
January 11, 2013
An SAC Capital Advisors LP unit will push to dismiss claims in a U.S. Securities and Exchange Commission suit over its alleged involvement in $276 million in insider trading related to an experimental Alzheimer's treatment, its lawyer said Friday.